The treatment of interstitial pneumonia due to dermatomyositis is determined by the specific condition of the patient. For example, in the early stage, small-dose glucocorticoids or combined immunosuppressant co-treatment can be applied.
1. Glucocorticoid therapy: such as prednisone acetate, methylprednisolone tablets, betamethasone and so on. It has a variety of effects such as anti-inflammatory, anti-toxic, anti-allergic, anti-shock, non-specific inhibition of immunity and antipyretic effect, which can prevent and stop the occurrence of immune inflammatory response and pathological immune response. It plays an important role in regulating the development, growth, metabolism and immune function of the body.
2. Immunosuppressant treatment: Generally, it is necessary to treat interstitial pneumonia at the same time when treating dermatomyositis. The immunosuppressants usually used are methotrexate, azathioprine, etc. Methotrexate is more effective in dermatomyositis and polymyositis, and can be given orally, static injection or intravenous drip.
Azathioprine is more effective for interstitial pneumonia in combination with prednisone. For some severe cases, it is advocated that patients be treated early with immunologic agents in combination with glucocorticoids. The above drugs must be used as prescribed by the doctor.
Dermatomyositis triggered interstitial pneumonia should be timely to the hospital rheumatology and immunology department, the development of standardized treatment programs, including adjusting the amount of hormones, as well as adjusting the amount and type of immunosuppressants, the patient should be individualized treatment.